David Macleod

Title: David Macleod: Innovator in Respiratory Treatment

Introduction

David Macleod is an accomplished inventor based in the United States. He has made significant contributions to the field of respiratory treatments, particularly through his innovative formulations. His work focuses on the combination of antibiotics for effective delivery in treating bacterial respiratory infections.

Latest Patents

David Macleod holds a notable patent titled "Aerosolized Fosfomycin/Aminoglycoside Combination For The Treatment Of Bacterial Respiratory Infections." This patent describes a formulation that combines fosfomycin and tobramycin for aerosolized delivery. The formulation is designed to inhibit susceptible bacteria effectively. It is prepared in a dual ampoule system, allowing for reconstitution to achieve a pH between 4.5 and 8.0, or as a dry powder. The method of treatment involves delivering the aerosol with a mass median aerodynamic diameter predominantly between 1 to 5 µ, produced by a jet or ultrasonic nebulizer or dry powder inhaler.

Career Highlights

David Macleod is currently associated with Corus Pharma, Inc., where he continues to develop innovative solutions for respiratory health. His work has been instrumental in advancing treatment options for patients suffering from bacterial infections in the respiratory tract.

Collaborations

David collaborates with William Baker, contributing to the development of effective treatment methodologies in their field.

Conclusion

David Macleod's contributions to respiratory treatment through his innovative formulations highlight his commitment to improving patient care. His work exemplifies the importance of collaboration and innovation in the medical field.